Shay Capital LLC Invests $366,000 in ABIVAX Société Anonyme (NASDAQ:ABVX)

Shay Capital LLC bought a new position in shares of ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 50,029 shares of the company's stock, valued at approximately $366,000. Shay Capital LLC owned 0.08% of ABIVAX Société Anonyme at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. R Squared Ltd acquired a new stake in shares of ABIVAX Société Anonyme during the 4th quarter worth $36,000. Bank of America Corp DE grew its holdings in shares of ABIVAX Société Anonyme by 56.1% during the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company's stock worth $41,000 after purchasing an additional 1,990 shares in the last quarter. Ameriprise Financial Inc. acquired a new stake in shares of ABIVAX Société Anonyme during the 4th quarter worth $85,000. Guggenheim Capital LLC acquired a new stake in shares of ABIVAX Société Anonyme during the 4th quarter worth $92,000. Finally, BNP Paribas Financial Markets boosted its stake in ABIVAX Société Anonyme by 47.5% in the fourth quarter. BNP Paribas Financial Markets now owns 19,244 shares of the company's stock valued at $141,000 after buying an additional 6,200 shares in the last quarter. Institutional investors own 47.91% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. JMP Securities reaffirmed a "market outperform" rating and issued a $33.00 price objective on shares of ABIVAX Société Anonyme in a research note on Wednesday, April 30th. Morgan Stanley reiterated an "equal weight" rating and issued a $12.00 target price on shares of ABIVAX Société Anonyme in a research report on Thursday, March 20th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $34.00.

ABIVAX Société Anonyme Trading Down 1.4%

ABVX stock traded down $0.08 during mid-day trading on Tuesday, reaching $5.80. The company's stock had a trading volume of 51,478 shares, compared to its average volume of 133,915. ABIVAX Société Anonyme has a 12 month low of $4.77 and a 12 month high of $14.72. The business's 50 day moving average price is $6.39 and its 200 day moving average price is $7.20.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.